[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Turku University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":700},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,49,82,107,131,160,187,213,240,271,306,333,360,386,408,430,457,477,498,529,557,585,616,647,678],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643164","parent-led-assessment-and-recognition-of-aom-using-digital-ear-imaging-100643164",false,"NCT07640568","Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging","PARENT-EAR","Inclusion Criteria:\n\n* At least one episode of AOM within the last 12 months\n* Family speaks fluent Finnish\n\nExclusion Criteria:\n\n* Tympanostomy tubes or perforation of the TM, or scheduled for upcoming tympanostomy\n* Middle ear fluid at the time of recruitment\n* Previously diagnosed hearing loss\n* Immunosuppressive disorder or medication, excluding inhaled corticosteroids\n* Anatomic defect or anomaly affecting the susceptibility to AOM\n* Previous otoscopy experience of the participating parent",true,"ALL","12 Months","47 Months",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on clinical expertise.\n\nDigital otoscopy combined with artificial intelligence (AI)-based image analysis has demonstrated high diagnostic accuracy in previous studies. In a recent study by our group, digital otoscopy with an automated neural network classifier reliably ruled out otitis media in children.\n\nThe PARENT-EAR randomized controlled pilot trial aims to evaluate whether parent-performed digital otoscopy at home, combined with retrospective AI analysis of captured TM images, can reduce physician visits due to suspicion of AOM. The study also assesses feasibility, diagnostic accuracy of parents after training, and potential effects on antibiotic use and healthcare utilization.\n\nMethods and outcomes The PARENT-EAR trial is a randomized controlled pilot trial conducted at Vaasa Central Hospital and Turku University Hospital. Recruitment will occur between September and December 2026 (extended if necessary), with follow-up ending May 31, 2027 (5-9 months per participant).\n\nChildren aged 12 to 47 months with at least one AOM episode in the past 12 months will be randomized 1:1 using permuted block randomization. Exclusion criteria include tympanostomy tubes, tympanic membrane perforation, middle ear effusion at recruitment, immunosuppression, previously diagnosed hearing loss or anatomical abnormalities predisposing to AOM, and otoscopy experience of the parent.\n\nIntervention group:\n\nParents receive a digital otoscope (The Ear Penguin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images\u002Fvideos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.\n\nControl group:\n\nStandard care without home otoscopy. Parents complete the same symptom diary and seek care according to usual practice.\n\nStatistical analyses will compare outcomes between groups. AI-based TM classification will be compared against expert panel evaluation.\n\nThis is a pilot study with a target sample size of 20 children per arm, limited by device availability.\n\nEthical aspects, data collection and handling The study will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all parents after provision of oral and written information. Participation is voluntary, and families may withdraw at any time. Investigators may discontinue participation if deemed in the child's best interest.\n\nThe digital otoscope is a CE-marked Class I medical device used solely for visual inspection of the tympanic membrane. Pneumatic pumps are not provided. Potential risks include minor ear canal abrasions or discomfort; serious adverse events are considered rare. Any adverse events will be managed according to standard clinical practice and reported to relevant authorities when required. The study is investigator-initiated. The device manufacturer provides the otoscopes but has no role in study design, data access, or analysis.\n\nData will be collected via paper symptom diaries, monthly REDCap questionnaires (University of Turku), and national electronic health records (Kanta). TM images and videos will be securely stored and imported into a research database with relevant metadata.\n\nAll data will be handled in accordance with the EU General Data Protection Regulation (GDPR 2016\u002F679). Study data will be pseudonymized and identified only by study ID numbers. The key linking personal identifiers to study IDs will be stored separately and securely. Paper diaries will be destroyed after digitalization. Consent includes permission to access health records and to use collected images and data for scientific purposes. Results will be published in peer-reviewed journals and as part of a doctoral thesis.",[29,30],"Acute Otitis Media","Otitis Media",[32,33,34,35],"acute otitis media","otitis media","digital otoscopy","telemedicine","NOT_YET_RECRUITING","2026-06-06",{"date":39,"type":40},"2026-06-10","ACTUAL",{"date":42,"type":23},"2026-09-01",{"date":44,"type":23},"2027-08-31",{"name":46,"class":47},"Turku University Hospital","OTHER_GOV",2,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100639804","randomized-clinical-trial-for-tonsil-surgery-in-adults-with-obstructive-sleep-apnea-and-enlarged-tonsils-100639804","NCT07580170","Randomized Clinical Trial for Tonsil Surgery in Adults With Obstructive Sleep Apnea and Enlarged Tonsils","Multicenter, National, Randomized, Patient-Blinded, Parallel Group, Non-Inferiority Trial To Compare Tonsillotomy Versus Extracapsular Tonsillectomy in Adults With Obstructive Sleep Apnea and Tonsil Hypertrophy: The TONOS Trial.","TONOS","Inclusion Criteria:\n\n* BMI \\\u003C 35\n* Tonsil size 2 - 4\n* Otherwise healthy patient fit for tonsil surgery\n* Apnea-hypopnea index \\> 15\n* Obstructive sleep apnea symptoms\n\nExclusion Criteria:\n\n* Pathological hemostasis or use of anticoagulation\n* Craniofacial deformities\n* Neurological condition with muscular hypotonia\n* Other surgical treatment for OSA","18 Years","65 Years",{"count":60,"type":23},132,[26],"The aim is to investigate whether the tissue-preserving tonsil surgery technique is as effective as complete tonsil removal in the treatment of obstructive sleep apnea. The primary outcome measure is the change in the apnea-hypopnea index (AHI) before surgery and at 4-6, 24, and 60 months after surgery.",[64,65],"Sleep Apnea, Obstructives","Tonsil Hypertrophy",[67,68,69,70,71,72],"sleep apnea","tonsillectomy","tonsillotomy","intracapsular tonsillectomy","adults","tonsil hypertrophy","2026-05-31",{"date":75,"type":40},"2026-06-03",{"date":77,"type":23},"2026-10-01",{"date":79,"type":23},"2036-01-01",{"name":46,"class":47},4,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100637115","recovery-from-tonsil-surgery-100637115","NCT07598201","Recovery From Tonsil Surgery.","Recovery From Tonsil Surgery (FINITE-2). A Randomized, Controlled, Single-blinded Trial Exploring the Recovery and Effectiveness of Two Tonsil Surgery Techniques in Adults.","FINITE-2","Inclusion Criteria:\n\n1. Age 18-65 years\n2. Recurrent or chronic tonsillitis (see above)\n3. Indication for surgical treatment\n4. Eligible for day care surgery\n\nExclusion Criteria:\n\n1. Peritonsillar abscess less than month ago\n2. Previous palatine tonsil surgery (excluding small incision or biopsy)\n3. Current or positive history of a malignant disease\n4. Anticoagulant medication\n5. Contraindication to non-steroidal anti-inflammatory drugs (NSAID) or paracetamol\n6. Other significant co-morbidity\n7. Other contraindications determined by the investigator",{"count":91,"type":23},90,[26],"The goal of this study is to optimize the duration of sick leave and the usage of opioids following partial tonsillar surgery in adults by comparing the recovery after extracapsular tonsillectomy (ECTE) with recovery after intracapsular tonsillectomy (ICTE). An additional objective is to confirm that ICTE is as effective as ECTE when comparing TOI-14 scores after 12 months post-operatively.\n\nThe main questions the study aims to answer are:\n\n* Is 10 days sick leave enough after partial tonsillectomy (ICTE)?\n* Are opioids needed at all after partial tonsillectomy (ICTE)?\n* Is ICTE as effective as ECTE when comparing TOI-14 symptom scores after 12 months from the surgery?\n\nAdult patients who are scheduled to tonsil surgery are randomised into 2 groups: ICTE and ECTE. Patients are blinded. Postoperatively they will answer structured questions about the recovery and effectiveness of the surgery. The last follow up survey is 60 months after the surgery.",[95,96],"Recurrent Tonsillitis","Chronic Tonsillitis",[70,98],"extracapsular tonsillectomy","2026-05-19",{"date":101,"type":40},"2026-05-20",{"date":103,"type":23},"2026-06-01",{"date":105,"type":23},"2030-12",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100630501","effective-implementation-of-the-physical-activity-and-motor-skills-intervention-for-3-6-year-old-children-with-cancer-empower-100630501","NCT07488494","Effective Implementation of the Physical Activity and Motor Skills Intervention for 3-6-year-old Children With Cancer (EMPOWER)","EMPOWER","Inclusion Criteria:\n\nCancer diagnosis at the age of 3 to 6 years\n\nExclusion Criteria:\n\nNo heart disease or neurological condition prohibiting physical activity -","3 Years","6 Years",{"count":22,"type":23},[26],"The study examines the association of digitally provided EMPOWER - exercise intervention on 3-6-year-old child's physical activity (PA), motor performance and quality of life (QoL) during and after cancer treatment. In addition, the factors that influence the feasibility of the intervention will be examined. The research is carried out in cooperation with Turku University of Applied Sciences, Turku and Tampere University Hospitals. Cancer treatments significantly reduce the amount of PA of the child impairing the normal motor development. Delay in normal motor development may cause childhood cancer survivors a higher risk of developing adverse health effects in adulthood. Data on children's PA and condition is collected using questionnaires and sensors. In addition, children's motor performance and QoL are examined through tests and questionnaires. The feasibility of the intervention will be examined from the parents and nursing staff through questionnaires and interviews.",[120],"Physical Activity During Cancer Treatment",[122],"physical activity enhancement","2026-03-18",{"date":125,"type":40},"2026-03-23",{"date":127,"type":23},"2026-03-01",{"date":129,"type":23},"2028-08-31",{"name":46,"class":47},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":138,"minAge":139,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":24,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":48},"100570239","study-on-recurrent-breast-cancer-and-repeated-radiation-therapy-100570239","NCT06704659","Study on Recurrent Breast Cancer and Repeated Radiation Therapy","RAY-no-BAN","Inclusion Criteria:\n\n* The patient has a diagnosed breast cancer or tumor area in the breast with a maximum diameter of 3 cm, where a previous breast-conserving surgery has been performed (either invasive breast cancer or carcinoma in situ, DCIS).\n\nThe patient has only a local recurrence, and imaging studies show no suspicion of metastases outside the breast (preoperative staging N0M0).\n\nAt least 3 years have passed since the completion of prior radiation therapy. The new breast cancer can be technically treated with another breast-conserving surgery using a technique that does not require tissue transfer from areas opposite the removed tumor to restore the shape of the breast.\n\nThe patient is at least 55 years old at the time of surgery. The patient is willing to participate in the study. The patient is capable of providing informed consent.\n\nExclusion Criteria:\n\n* A booster dose, also known as a \"boost,\" was administered during prior radiation therapy.\n\nPreoperative assessments suggest multifocal breast cancer, with the tumor area to be removed exceeding 3 cm.\n\nThe planned radiation therapy per the study protocol cannot be administered due to factors such as shoulder joint stiffness, a pacemaker located in the radiation field, or a skin condition (e.g., scleroderma).\n\nThe patient is unable to provide informed consent or is unwilling to participate in the study.\n\nMetastases outside the breast (e.g., axillary or distant metastases) are present.","FEMALE","55 Years",{"count":141,"type":23},60,[26],"This study explores whether recurrent breast cancer can be safely treated with breast-conserving surgery and repeated radiation therapy in cases where patients have previously undergone radiation. Traditionally, recurrent breast cancer has been treated by removing the entire breast. However, recent research has shown that in certain situations, it may be possible to preserve the breast.\n\nThe study will collect data on the safety of this treatment approach and its effects on patients. The treatment follows standard breast cancer care practices, involving 30 patients from Helsinki and Turku University Hospitals. Patients are carefully selected based on specific criteria, such as tumor size, localization, and prior treatment history. Special attention is given to the planning of radiation therapy and surgical techniques.\n\nThe goal is to develop new treatment strategies that allow breast preservation even in cases of recurrent breast cancer, providing patients with high-quality and individualized care.",[145],"Recurrent Breast Carcinoma",[147,148,149,150],"Breast cancer","Recurrence","Repeat radiation therapy","Radiation therapy","RECRUITING","2026-03-06",{"date":154,"type":40},"2026-03-09",{"date":156,"type":40},"2024-12-01",{"date":158,"type":23},"2030-12-31",{"name":46,"class":47},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":17,"sex":18,"minAge":166,"maxAge":115,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},"100616812","administration-of-the-nasal-influenza-vaccine-to-children-in-daycare-or-at-a-healthcare-facility-100616812","NCT07310472","Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility","Inclusion Criteria:\n\n* Attending early childhood education (daycare) in the city of Turku\n\nExclusion Criteria:\n\n* No exclusion criteria","2 Years",{"count":168,"type":23},6000,[26],"The goal of this intervention study is to learn if giving children influenza vaccinations in early childhood education facilities (i.e., daycare) will increase vaccination coverage compared to giving vaccinations only at healthcare. The main question it aims to answer is:\n\n• Does offering children nasal influenza vaccine in daycare result in higher proportion of children getting influenza vaccine.\n\nResearchers will compare daycare setting and healthcare setting as the location of giving influenza vaccines to children to see if more children will get vaccinated if they have an opportunity to receive nasal influenza vaccine at daycare.\n\nParticipants in the intervention group will:\n\n• Have the opportunity to receive influenza vaccine in the daycare or in the healthcare\n\nParticipants in the comparison group will:\n\n• Have the opportunity to receive influenza vaccine in the healthcare only",[172],"Influenza Vaccination",[174,175,176,177],"Influenza","Children","Vaccination coverage","Nasal influenza vaccine","2026-01-20",{"date":180,"type":40},"2026-01-22",{"date":182,"type":40},"2025-10-27",{"date":184,"type":23},"2026-03-31",{"name":46,"class":47},1,{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":18,"minAge":194,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":186},"100489107","phase-3-neonatal-brain-ultrasound-with-ceus-and-elastography-100489107","NCT05648812","Neonatal Brain Ultrasound With CEUS and Elastography","Contrast Enhanced Ultrasound and Elastography of the Neonatal Brain","Inclusion Criteria:\n\n* Babies less than 7 months treated at the neonatal units of Turku University hospital\n\nExclusion Criteria:\n\n* Pre-known genetic disease\n* Difficult congenital malformations that need surgical treatment\n* Central nervous system tumors\n* Weight less than 2,5 kg during examination\n* Medical history of SonoVue hypersensitivity\n* Uncontrolled systemic hypertension\n* Systolic pulmonary artery pressure \\> 90 mmHg\n* Unstable cardiovascular state","1 Minute","6 Months",{"count":197,"type":23},100,[199],"PHASE3","The aim of our study is to investigate changes of brain perfusion and elasticity in neonates during the time that a neonate is adapting to live outside the womb and during diseases that are suspected to affect neonatal brain perfusion. We use contrast enhanced ultrasound (sulphur hexafluoride) and ultrasound-assisted elastography to evaluate the state of brain perfusion. We will study neonates recruited from the Neonatal Units of Turku University Hospital.",[202,203,204],"Neonatal Hypoxic Ischemic Encephalopathy","Neonatal Stroke","Neonatal Encephalopathy, Unspecified","2026-01-13",{"date":207,"type":40},"2026-01-15",{"date":209,"type":40},"2024-01-01",{"date":211,"type":23},"2029-12",{"name":46,"class":47},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":24,"phases":223,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":239},"100616468","pilot-study-effects-of-ccp-intervention-on-nicu-environment-and-preterm-infants-development-100616468","NCT07306000","Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development","Effects of Close Collaboration With Parents Intervention on NICU Care Environments and Long-term Development of Preterm Infants: a Pilot Study","Inclusion Criteria:\n\n* preterm infants born below 32 weeks of gestation and\u002For weighing \\\u003C 1500 g who receive long-term follow-up at each study site.\n\nExclusion Criteria:\n\n* the infant has any major anomalies\n* the infants are triplets or higher order\n* the infant's condition is critical and the survival is uncertain\n* the parents cannot understand the informed consent form in Korean or in Japanese","1 Hour","7 Days",{"count":197,"type":23},[26],"Close Collaboration with Parents intervention is an evidence-based educational intervention for the entire multi-professional staff of neonatal intensive care units (NICUs). The goal of the intervention is to strengthen partnership between staff and parents, enhance parental participation in infant care. There are no studies yet about the effects of the Close Collaboration with Parents intervention on the long-term neurodevelopment and socio-emotional development of very preterm infants and their interaction with their parents. Accordingly, a multicenter cluster randomized controlled trial is planned. Prior to initiating this large-scale study, it is essential to validate the measurement instruments. Therefore, a pilot study will be conducted to assess their feasibility and to determine the appropriate sample size.",[226,227],"Preterm Infant Development","Preterm Infant Health",[229,230],"close collaboration with parents","family-centered care","2025-12-29",{"date":233,"type":40},"2025-12-31",{"date":235,"type":40},"2025-12-22",{"date":237,"type":23},"2028-12-31",{"name":46,"class":47},3,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":24,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":186},"100617303","neuroprotective-effect-of-mild-hypothermia-versus-normothermia-during-cardiopulmonary-bypass-of-coronary-artery-surgery-100617303","NCT07316868","Neuroprotective Effect of Mild Hypothermia Versus Normothermia During Cardiopulmonary Bypass of Coronary Artery Surgery","Neuroprotective Effect of Mild Hypothermia as Compared With Normothermia During Cardiopulmonary Bypass of Coronary Artery Bypass Grafting - A Single-center Randomized Controlled Trial","HYPNOCABG","Inclusion Criteria:\n\n1. Informed consent obtained\n2. Age of \\>18 years\n3. Undergoing elective or subacute coronary artery bypass grafting\n\nExclusion Criteria:\n\n1. An emergency case\n2. A history of stroke\n3. A history of intracranial bleeding\n4. A history of transient ischemic attack (TIA)\n5. A history of neurodegenerative diseases such as Alzheimer's, multiple sclerosis\n6. The subject is known to have a clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the subject to participate in this clinical trial.\n7. Presence of implants or foreign bodies which are not known to be MRI safe",{"count":249,"type":23},160,[26],"In high-income countries, coronary artery bypass grafting (CABG) remains a common procedure, with approximately 36.7 operations per 100,000 inhabitants annually, corresponding to about 136,000 procedures in the European Union. This highlights the substantial healthcare burden and the need to optimize surgical outcomes. Cardiopulmonary bypass (CPB) is a fundamental component of cardiac surgery, ensuring extracorporeal perfusion of vital organs.\n\nHypothermic CPB has historically been widely used for organ protection due to its presumed neuroprotective mechanisms. However, evidence demonstrating its superiority over normothermic CPB remains inconclusive. In its 2024 guidelines, the European Association for Cardio-Thoracic Surgery recommends considering normothermia (≥35 °C) to reduce postoperative neurocognitive dysfunction (Class II, Level A). This recommendation is primarily based on two meta-analyses, but the underlying studies show methodological heterogeneity, outdated practices, and limited applicability to contemporary cardiac surgery. Importantly, the guidelines acknowledge the need for large randomized controlled trials to define optimal target temperature management (TTM) during CPB.\n\nPrevious diffusion-weighted MRI studies have demonstrated silent ischemic brain lesions in approximately 30% of CABG patients, with postoperative neurocognitive decline occurring in a similar proportion. However, no significant differences have been shown between normothermic and hypothermic CPB. Diffusion tensor imaging (DTI) extends conventional diffusion imaging by enabling detailed assessment of white matter microstructure and tractography. Fractional anisotropy (FA), a key DTI metric, has demonstrated prognostic value in various neurological conditions but has not yet been applied in CABG patients.\n\nBlood-based biomarkers, including glial fibrillary acidic protein, neurofilament light chain, neuron-specific enolase, and total tau, offer complementary insights into brain injury but have not been studied in combination with DTI in this population.\n\nThis study will compare mild hypothermic (33-34 °C) and normothermic (36.5 °C) CPB to evaluate their neuroprotective effects using advanced MRI techniques and blood-based biomarkers. The primary aim is to determine whether mild hypothermia provides superior neuroprotection following CABG. Secondary objectives include assessing white matter injury evolution, global ischemic burden, associations with biomarkers and neurocognitive decline, and developing integrated prognostic models to improve outcomes in CABG patients.",[253,254],"Coronary Artery Disease","Brain Injury",[256,257,258,259,260,261,262],"hypothermia","normothermia","cardiopulmonary bypass","coronary artery bypass grafting","diffusion tensor imaging","neuroprotection","biomarkers","2025-12-18",{"date":265,"type":40},"2026-01-05",{"date":267,"type":23},"2026-01-01",{"date":269,"type":23},"2029-12-31",{"name":46,"class":47},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":17,"sex":138,"minAge":57,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":282,"phases":4,"briefSummary":283,"conditions":284,"keywords":291,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":186},"100613917","usability-study-of-gestational-and-postpartum-weight-management-program-100613917","NCT07272824","Usability Study of Gestational and Postpartum Weight Management Program","Usability Study of Gestational and 6 Months Postpartum Weight Management Program - Hope D","Hope-D_Use","Inclusion Criteria:\n\n* General pregnant women with prepregnancy BMI at least 30 kg\u002Fm2\n* Competence in using the digital care pathway and electronic maternity card\n\nExclusion Criteria:\n\n\\- Significant difficulty in cooperating (e.g. inadequate Finnish language skills)","50 Years",{"count":281,"type":23},30,"OBSERVATIONAL","The principal aim of this study is to evaluate the usability of the Hope-D gestational and 6 months postpartum weight management program. We will evaluate the usability, functionality, and acceptability of the developed Hope-D weight management program that includes digital pathway for weight management, general or individual weight management plan and individual or group coaching for weight management from pregnancy to 6 months postpartum.",[285,286,287,288,289,290],"Pregnancy","Postpartum","Obese Pregnant Women","Weight Management","Digital Intervention","Usability",[292,293,294,295,296,297],"Hope-D","digital pathway","Gestational weight management","Postpartum weight management","gestational weight management plan","coaching","2025-12-16",{"date":300,"type":40},"2025-12-23",{"date":302,"type":40},"2025-12-09",{"date":304,"type":23},"2026-01-31",{"name":46,"class":47},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":138,"minAge":57,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":282,"phases":4,"briefSummary":314,"conditions":315,"keywords":322,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":186},"100613914","maternal-informing-on-labor-induction-impact-on-childbirth-experience-100613914","NCT07272785","Maternal Informing on Labor Induction: Impact on Childbirth Experience","Inclusion Criteria:\n\n* Planned induction of labor at the antenatal ward or at the outpatient clinic\n* Adequate language skills (Finnish, Swedish, English)\n\nExclusion Criteria:\n\n* Induction at the delivery ward or at the obstetric emergency care clinic\n* Spontaneous onset of labor or a planned cesarean delivery\n* Age below 18 years at the time of recruitment",{"count":313,"type":23},50,"The aim of this study is to explore the information provided to mothers about labor induction and its connection to their childbirth experience. In addition, the study examines how the use of social media may influence the birth experience among patients undergoing labor induction.",[316,317,285,318,319,320,321],"Labor, Induced","Labor, Obstetric","Humans","Prospective Study","Prospective Study , Questionaires","Childbirth Experience",[323,324,285,325,326],"Childbirth experience","Induction of labor","Childbirth","Obstetrics",{"date":300,"type":40},{"date":329,"type":40},"2025-12-08",{"date":331,"type":23},"2026-06",{"name":46,"class":47},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":24,"phases":342,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":186},"100613913","phase-2-colon-cancer-diagnosis-with-fapi-pet-imaging-100613913","NCT07272772","Colon Cancer Diagnosis With FAPI-PET Imaging","Diagnostic Efficacy of 18F-FAPI-74 PET\u002FCT in Patients With Colon Cancer","Inclusion Criteria:\n\n* Patients with primary colon cancer with suspicion of mesenteric lymph node metastases in computed tomography before primary cancer operation\n* Patients with primary colon cancer with potentially curable metastases\n* Patients with suspected metastasis or local recurrence in computed tomography and\u002For elevated carcinoembryonic antigen (CEA) in cancer surveillance\n* WHO performance score 0-2\n* Patient signs informed consent form after receiving written information\n\nExclusion Criteria:\n\n* Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included\n* Patient is not able to understand purpose of study\n* Medical conditions prohibiting whole body PET-CT","85 Years",{"count":197,"type":23},[343,199],"PHASE2","Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targeting a protein that is overexpressed by cancer-associated fibroblasts presents a potential new PET imaging tool.\n\nThe objective of this prospective study is to evaluate diagnostic efficacy of 18F-FAPI-74 PET\u002FCT in patients with colon cancer. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with colon cancer in primary staging and when suspected recurrence. 100 patients with colon cancer are enrolled and PET\u002FCT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.",[346],"Colon Cancer",[348,349,350,351,352],"Positron Emission Tomography","FAPI","Diagnostics","Imaging","Staging","2025-11-26",{"date":302,"type":40},{"date":356,"type":40},"2024-10-09",{"date":358,"type":23},"2026-10",{"name":46,"class":47},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":17,"sex":138,"minAge":57,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":282,"phases":4,"briefSummary":368,"conditions":369,"keywords":372,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":48},"100542523","noninvasive-evaluation-of-fetal-hyperinsulinemia-with-ultrasound-radiomics-100542523","NCT06343974","Noninvasive Evaluation of Fetal Hyperinsulinemia With Ultrasound Radiomics","Inclusion Criteria:\n\n* Age between 18-45 years\n* Capable to give an informed consent\n* Singleton pregnancy\n* Planning to deliver in Turku University Hospital\n* Maternal BMI \\\u003C 40\n* Gestational age should be confirmed by first trimester ultrasound\n* Normal oral glucose tolerance test (OGTT) at 24-28 gestational weeks in controls\n\nExclusion Criteria:\n\n* Major fetal chromosomal, genetic, or structural anomaly\n* Fetal growth restriction, or birth weight \\\u003C 10th centile\n* Birth weight \\> 90th centile or polyhydramnios in the controls\n* Non-reassuring fetal status requiring immediate treatment, or intrauterine fetal demise\n* Verified fetal infection (e.g. cytomegalovirus, toxoplasma, hepatitis B and C), excluding bacterial infection due to intrapartum chorioamnionitis\n* Placenta accreta spectrum disorder\n* Major maternal medical condition requiring systemic pharmacological treatment, other than non-severe hypertension, hypothyroidism, asthma, mild psychiatric disorders, etc.\n* Alcohol or tobacco use, or substance abuse in pregnancy","45 Years",{"count":141,"type":23},"The goal of this observational study is to compare fetal liver ultrasound radiomics between pregnancies complicated by type 1 diabetes and healthy controls.\n\nThe main questions it aims to answer are:\n\n* Are fetal liver ultrasound radiomic features reproducible?\n* Does fetal liver ultrasound radiomics differ between pregnancies complicated by type 1 diabetes and healthy controls?\n\nParticipants will undergo ultrasound examination to collect ultrasound data for the analyses.",[370,371],"Pregnancy in Diabetic","Diabetes Mellitus, Type 1",[373,374,375,376,377,378],"ultrasonography","fetus","radiomics","hyperinsulinemia","liver","pregnancy","2025-11-23",{"date":381,"type":40},"2025-11-28",{"date":383,"type":40},"2024-10-11",{"date":103,"type":23},{"name":46,"class":47},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":282,"phases":4,"briefSummary":394,"conditions":395,"keywords":397,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":407,"locationsCount":186},"100608753","self-assessment-of-tonsil-size-100608753","NCT07205653","Self-assessment of Tonsil Size","Validity of Patients' Self-assessment of Tonsil Size","Exclusion Criteria:\n\n* Experience in clinical work with patients\n* Prior tonsillectomy",{"count":91,"type":23},"The participants receive instructions on two tonsil size classification scales and then, using a tongue depressor as well as their mobile phone camera and\u002For a flashlight and a mirror, the participants assess the size of their own tonsils on two scales.\n\nAfter the self-assessment, a medical student and two ear, nose, and throat (ENT) specialists evaluate the participants' tonsil size using a tongue depressor and a headlamp, applying the same scales.\n\nThe objective of this study is to demonstrate that patient self-assessment constitutes a sufficiently accurate method for evaluating tonsil size. Furthermore, it aims to show that patients experiencing conditions such as sleep apnea or swallowing difficulties can, on the basis of their own assessment, be appropriately referred to an otolaryngologist for surgical evaluation, thereby conserving healthcare resources and reducing the time burden for patients.",[396],"Tonsillar Hypertrophy",[398,399,400],"tonsil size","tonsillar hypertrophy","self-assessment","2025-10-02",{"date":403,"type":40},"2025-10-03",{"date":405,"type":23},"2025-10-20",{"date":267,"type":23},{"name":46,"class":47},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":17,"sex":138,"minAge":57,"maxAge":4,"enrollmentInfo":415,"targetDuration":417,"studyType":282,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":186},"100278014","vaginal-and-oral-microbiome-crosstalk-100278014","NCT02898818","Vaginal and Oral Microbiome Crosstalk","EMMI - Emättimen Mikrobiomi - Emättimen ja Suun Limakalvojen Vuorovaikutus","Inclusion Criteria:\n\n* patients coming to Turku University Hospital Dermato-Venereology or Gynaecology Departments or to family planning clinics in The wellbeing services county of Southwest Finland for previously mentioned reasons\n\nExclusion Criteria:\n\n* those not meeting the criteria",{"count":416,"type":23},520,"5 Years","To study the vaginal and oral microbiome by swab samples. On selected cases, also papa smear will be studied.",[420,421],"Healthy","Vaginal Discharge","2025-09-16",{"date":424,"type":40},"2025-09-22",{"date":426,"type":40},"2017-04-19",{"date":428,"type":23},"2027-09",{"name":46,"class":47},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":437,"maxAge":57,"enrollmentInfo":438,"targetDuration":4,"studyType":24,"phases":440,"briefSummary":441,"conditions":442,"keywords":445,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":456,"locationsCount":186},"100562656","the-effectiveness-of-group-schema-therapy-in-the-treatment-of-borderline-symptoms-in-adolescents-100562656","NCT06606002","The Effectiveness of Group Schema Therapy in the Treatment of Borderline Symptoms in Adolescents","The Effectiveness of Group Schema Therapy Utilizing Video Material in the Treatment of Borderline Symptoms in Adolescents: A Randomized and Controlled Intervention Study","Inclusion Criteria:\n\n* The participant fulfills at least three diagnostic criteria for borderline personality disorder as assessed by means of the SCID-II structured clinical interview\n* The participant and the participant's parent(s) are able to commit to the research protocol for the entire duration of the study\n* The participant is able to participate in a research intervention in Finnish and fill out the study questionnaires in Finnish\n\nExclusion Criteria:\n\n* The participant currently has psychotic symptoms or a serious risk of suicide\n* The participant has been diagnosed with an intellectual disability or an autism spectrum disorder\n* The main clinical diagnosis of the participant is a substance abuse disorder or substance use would endanger commitment to the research intervention\n* The participant has another illness or symptom that endangers the participant's ability to complete the study\n* The participant receives some other treatment specifically aimed at borderline personality disorder symptoms","15 Years",{"count":439,"type":23},64,[26],"The goal of this randomized and controlled trial is to assess the effectiveness of group schema therapy in the treatment of adolescents with borderline symptoms. The intervention utilizes self-recorded video material as an experiential method. The intervention comprises 30 group sessions and 8 individual sessions. Additionally, there are group sessions for the participants' parents. Participants in the control group receive treatment as usual.",[443,444],"Borderline Symptoms","Borderline Personality Disorder",[446,447,448,449],"adolescents","borderline disorder","schema therapy","randomized controlled study","2025-09-04",{"date":452,"type":40},"2025-09-11",{"date":454,"type":40},"2025-08-01",{"date":211,"type":23},{"name":46,"class":47},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":340,"enrollmentInfo":464,"targetDuration":4,"studyType":24,"phases":465,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":475,"leadSponsor":476,"locationsCount":186},"100600523","phase-2-pancreatic-cancer-diagnosis-with-fapi-pet-imaging-100600523","NCT07098598","Pancreatic Cancer Diagnosis With FAPI-PET Imaging","Diagnostic Efficacy of 18F-FAPI-74 PET\u002FCT in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Suspected primary or recurrent pancreatic cancer\n* Subjects must be male or female aged 18-85 years.\n* WHO performance score 0-2.\n* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n* Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.\n* Study subject is not able to understand the purpose of the study.\n* Medical conditions prohibiting whole-body PET\u002FCT imaging.",{"count":197,"type":23},[343,199],"Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up. Conventional PET\u002FCT with 18F-labelled fluorodeoxyglucose (18F-FDG) has its limitations and therefore has a secondary role in imaging pancreatic cancer patients. These conventional imaging methods are good in detecting primary tumors and distant metastasis but poor in detecting local lymph node metastasis. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targets FAP, a protein overexpressed in cancer-associated fibroblasts. It presents a potential new PET imagining tool.\n\nThe objective of this prospective diagnostic study is to evaluate the diagnostic efficacy of 18F-FAPI-74 PET\u002FCT in patients with PC. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with PC in primary staging and when suspected recurrence. 100 patients with PC are enrolled on whom PET\u002FCT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.",[348,468,349,350,469,470,471,352],"Pancreatic Cancer","Recurrent Pancreatic Cancer","Oncologic Surgery","Imaging, Diagnostic","2025-07-31",{"date":454,"type":40},{"date":356,"type":40},{"date":358,"type":23},{"name":46,"class":47},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":18,"minAge":483,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":24,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":497,"locationsCount":186},"100371769","3d-autotransplantation-of-teeth-100371769","NCT04120688","3D Autotransplantation of Teeth","Inclusion Criteria:\n\n* Need for tooth transplantation\n* Open apex tooth available for transplantation\n\nExclusion Criteria:\n\n* Facial syndrome\n* Chronic facial pain\n* Allergy to replica material","9 Years","23 Years",{"count":486,"type":23},120,[26],"The study aims to clarify the usefulness of 3D-printed replicas in association with autotransplantation of teeth in children and young adults.",[490],"Tooth Loss","2025-05-09",{"date":493,"type":40},"2025-05-14",{"date":495,"type":40},"2020-03-09",{"date":233,"type":23},{"name":46,"class":47},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":506,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":24,"phases":509,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":186},"100591020","resilience-to-antibiotic-induced-obesogenic-microbiota-discovering-mechanism-of-microbiota-modulation-100591020","NCT06974994","Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation","Resilience to Antibiotic-induced Obesogenic Microbiota Vertically Transferred to the Neonatal Gut: Discovering Mechanism of Microbiota Modulation","ReCoverHealth","Inclusion Criteria:\n\nPregnant women (n=125) and their newborn children who receive antibiotic treatment at delivery.\n\nExclusion Criteria:\n\n* Chorioamnionitis\n* Pre-eclampsia and hepatogestosis\n* Suspected malformation or serious condition of the foetus and neonates\n* Serious infection or other conditions not permitting breast milk feeding","2 Hours",{"count":508,"type":23},125,[26],"The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.",[512],"Healthy Newborn Infants",[514,515,516,517,518,519,520,521],"antibiotics","human milk oligosaccharides","probiotics","newborn","microbiome","microbiota","obesity","infectious diseases","2025-05-07",{"date":524,"type":40},"2025-05-16",{"date":526,"type":40},"2024-05-08",{"date":211,"type":23},{"name":46,"class":47},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":537,"maxAge":538,"enrollmentInfo":539,"targetDuration":4,"studyType":24,"phases":541,"briefSummary":542,"conditions":543,"keywords":546,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":555,"leadSponsor":556,"locationsCount":48},"100587891","phase-3-pooled-human-plasma-vs-crystalloid-in-the-management-of-children-undergoing-instrumented-spinal-fusion-for-scoliosis-100587891","NCT06934278","Pooled Human Plasma vs Crystalloid in The Management of Children Undergoing Instrumented Spinal Fusion for Scoliosis","Pooled Human Plasma vs Crystalloid in The Management of Children Undergoing Instrumented Spinal Fusion for Scoliosis: A Double-Blind, Randomized Clinical Trial","OCTAGON","Inclusion Criteria:\n\n* Written informed consent.\n* Aged between 10 and 21 years of age\n* Scoliosis requiring posterior scoliosis surgery using all pedicle screw technique for AIS (\\>45-degree major curve) or NMS (\\>50-degree major curve)\n* Normal whole spine MRI except for the spinal deformity (only for patients with adolescent idiopathic scoliosis as patients with neuromuscular scoliosis do not typically undergo MR images as they would need general anaesthesia)\n\nExclusion Criteria:\n\n* Immunoglobulin A-deficiency\n* Need for anteroposterior surgery\n* Need for three column vertebral resection\n* Smoking\n* Diabetes mellitus\n* Abnormalities in blood coagulation (thromboplastin time below above or below of normal values, 70-130%)\n* Blood trombosytes less than 150 x E9\u002Fl\n* Body mass index over 40\n* Allergy or hypersensitivity to study medications or their ingredients\n* Pregnancy or breast-feeding, aim of becoming pregnant during the study.\n* Participation in another study and receipt of any other investigational agent during 2 year period of current investigation\n* Inability to provide written informed consent\n* Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study.\n* A history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements.\n* Known history of, or documented positive hepatitis B or C or HIV infection Prior or concurrent malignancy\n* Aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 3 x upper-limit of normal\n* Creatinine clearance (CrCl) \\\u003C 60 ml\u002Fmin measured by 24-hour urine collection or estimated from the Cockcroft and Gault formula\n* Clinically significant ECG findings as judged by the investigator\n* Amiodarone medication\n* Hyperkalemia\n* Renal insufficiency\n* AV-block\n* Metabolic or respiratory alkalosis\n* Hypochlorhydria\n* Hypersensitivity for active component or additives.","10 Years","21 Years",{"count":540,"type":23},194,[199],"OCTAGON trial is a randomized, double-blinded, parallel-group non-inferiority multicenter (Helsinki and Turku University Hospitals, Finland) clinical trial according to CONSORT criteria.\n\n194 adolescents with idiopathic (major curve \\> 45 degrees) or neuromuscular scoliosis (major curve \\> 50 degrees) are enrolled for the OCTAGON trial comparing pooled human plasma (Octaplas, 10mL\u002Fkg, active management) vs. Plasmalyte (10 mL\u002Fkg, placebo) before incision as part of the normal intraoperative fluid therapy. Data is collected at baseline and at each follow-up until a minimum of 2-year follow-up.\n\nOutcomes Outcomes for the OCTAGON trial include 1) intraoperative blood loss (in mL, primary outcome) and the need for allogenic red blood cell infusion (percentage of patients). Secondary outcomes include health-related quality of life (Scoliosis Research Society 24 outcome questionnaire), postoperative pain (48-hour opioid consumption), operative time (hours), drain output (mL), hidden blood loss (mL), hospital stay, and complications (skin reactions, TRALI, deep surgical site infection, neurologic deficit).\n\nResearch questions and hypothesis Does prophylactic use of pooled human plasma decrease intraoperative blood loss in adolescents undergoing instrumented spinal fusion for scoliosis? We hypothesize that pooled human plasma will reduce intraoperative and total blood loss by 25% resulting in lower need for blood transfusion and fewer surgical site infections.\n\nObjectives To compare the effect of pooled human plasma vs. crystalloid fluids on intraoperative bleeding and total blood loss (drain output and hidden blood loss) in children undergoing posterior spinal fusion for AIS and NMS. Adverse events will be recorded and reported as minor (skin reaction) or major (severe allergic reaction, transfusion related acute lung injury, TRALI, deep surgical site infection, neurologic injury).\n\nEthical aspects The PHP trial has been evaluated via European regulatory authority (EU CT: 2024-514857-31-00) and by Fimea (FIMEA\u002F2024\u002F006588). Informed consent is obtained from the parent(s). Results will be disseminated in high-quality peer-reviewed publications.\n\nThe individual patient safety and high-quality management of fractures and scoliosis is a priority in this trial. The randomization can be opened at any stage of the treatment process. Based on the clinical decision the randomized treatment can be terminated and treatment provided accord-ing to clinical decision making even if results will be evaluated using the intention to treat princi-ple. Pain management will be prioritized in every clinical scenario and parental presence is always possible.",[544,545],"Adolescent Idiopathic Scoliosis (AIS)","Neuromuscular Scoliosis",[547,548,549,550,551],"adolescent idiopathic scoliosis","neuromuscular scoliosis","pooled human plasma","randomized clinical trial","double-blind placebo controlled","2025-05-02",{"date":522,"type":40},{"date":552,"type":40},{"date":158,"type":23},{"name":46,"class":47},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":566,"briefSummary":567,"conditions":568,"keywords":575,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":583,"locationsCount":584},"100415967","phase-2-effect-of-xenon-on-brain-injury-after-aneurysmal-subarachnoid-hemorrhage-100415967","NCT04696523","Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage","Effect of Xenon on Brain Injury, Neurological Outcome and Survival in Patients After Aneurysmal Subarachnoid Hemorrhage","Xe-SAH","Inclusion Criteria:\n\nTo be considered eligible to participate in this study, a SAH subject must meet the inclusion criteria listed below:\n\n1. Informed consent obtained from the next of kin or legal representative\n2. Aneurysmal subarachnoid hemorrhage visible on CTA or DSA.\n3. Deterioration of consciousness to Hunt-Hess 3-5\n4. Age of ≥ 18 years\n5. Intubated.\n6. GCS 3-12 obtained off neuromuscular blocking agents\n7. Xenon treatment can be started within 6 hours after onset of SAH symptoms\n\nExclusion Criteria:\n\nAn aSAH subject may not be enrolled in the trial if he\u002Fshe meets any one of the exclusion criteria below:\n\n1. Acute or chronic traumatic brain injury\n2. Maximum diameter of intracerebral hemorrhage \\> 2.5 cm\n3. Pneumothorax or pneumomediastinum,\n4. Acute lung injury requiring ≥ 60% FIO2 (fraction of inspired oxygen).\n5. Systolic arterial pressure \\\u003C 80 mmHg or mean arterial pressure \\\u003C 60 mmHg for over 30 min period\n6. Bilaterally fixed and dilated pupils\n7. Positive pregnancy test, known pregnancy, or current breast-feeding\n8. Neurological deficiency due to traumatic brain injury or other neurological illness\n9. Imminent death or current life-threatening disease\n10. Current enrollment in another interventional study\n11. The subject is known to have clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the subject to participate in this clinical trial.\n12. Presence of implants or foreign bodies which are not known to be MRI safe",{"count":249,"type":23},[343],"An investigator-initiated clinical drug study\n\nMain Objective:\n\nTo explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH).\n\nPrimary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI).\n\nAfter confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups:\n\nControl group: Standard of Care (SOC) group: Air\u002Foxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air\u002Foxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug\u002Ftreatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen\u002Fair.\n\nComparative drug(s)\u002Fplacebo\u002Ftreatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports.\n\nDuration of treatment: 24 hours\n\nAssessments:\n\nBaseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered.\n\nAcute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https:\u002F\u002Fwww.commondataelements.ninds.nih.gov\u002FSAH.aspx#tab=Data\\_Standards.",[569,570,571,572,573,574],"Subarachnoid Hemorrhage, Aneurysmal","Cerebral Injury","Cerebral Ischemia","Cerebral Infarction","Cardiac Event","Cardiac Failure",[576],"xenon, neuroprotection, aneurysmal subarachnoid hemorrhage","2025-04-28",{"date":579,"type":40},"2025-05-01",{"date":581,"type":40},"2025-04-22",{"date":269,"type":23},{"name":46,"class":47},7,{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":282,"phases":4,"briefSummary":595,"conditions":596,"keywords":601,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":615,"locationsCount":186},"100558495","the-effect-of-cancer-treatments-on-speech-perception-in-noise-cognition-and-hearing-related-quality-of-life-100558495","NCT06551857","The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life","CaSPiN","Inclusion Criteria:\n\n* written informed consent\n* native Finnish speaker\n* age-normative hearing\n* for participants in the treatment arms: diagnosis of a malignancy that will be treated with curative intent with any of the following: 1) Cisplatin as the main chemotherapeutic agent, 2) oxaliplatin as the main chemotherapeutic agent, 3) cisplatin-based chemoradiation therapy in the head and neck region, 4) radiation therapy in the head and neck region\n\nExclusion Criteria:\n\n* inability to provide written informed consent\n* Current or prior major otological condition that has affected or has had the potential to affect hearing\n* Conductive or asymmetric sensorineural HL of any severity\n* Severe sensorineural HL\n* Prior malignancy treated with chemotherapeutics or radiation therapy\n* Prior use of ototoxic medications\n* Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the trial, or may influence the result of the trial.\n* Any condition that, in the opinion of the investigator, would interfere with adherence to the trial requirements.\n\nFor participants in the treatment arms:\n\n* Allergy or hypersensitivity to trial medications or their ingredients\n* Pregnancy or breast-feeding, aim of becoming pregnant during the trial.","75 Years",{"count":594,"type":23},250,"The study will assess the effect of cancer treatments on speech perception in noise, cognition, and hearing-related quality of life by monitoring 200 cancer patients receiving standard care for their underlying malignancy.",[597,598,599,600],"Cancer","Hearing Loss Ototoxic","Cognitive Decline","Quality of Life",[602,603,604,605,606,607,608],"speech perception in noise","ototoxicity","hearing loss","cancer","cisplatin","oxaliplatin","cognition","2025-04-12",{"date":611,"type":40},"2025-04-16",{"date":613,"type":40},"2024-10-02",{"date":158,"type":23},{"name":46,"class":47},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":623,"targetDuration":624,"studyType":282,"phases":4,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":645,"leadSponsor":646,"locationsCount":4},"100587336","long-term-recovery-and-microbiota-gut-brain-axis-disruption-after-traumatic-brain-injury-100587336","NCT06927063","Long-term Recovery and Microbiota-Gut-Brain Axis Disruption After Traumatic Brain Injury","OVERCOME-TBI","Inclusion Criteria:\n\n* All those who are alive and give their consent will be included from our previous prospective studies (TBIcare or PACoS-TBI)\n\nExclusion Criteria (neurological and imaging studies):\n\n* For patients with TBI there are no exclusion criteria, and all eligible patients who give consent will be recruited\n* Those patients and controls with contraindication for head MRI (MRI-incompatible heart pacemaker, weight over 200 kg, mechanical heart valve prosthesis, first trimester of pregnancy, orbital area tattoo) will not undergo head MRI. Instead, they we will undergo the other assessments\n* For controls, those who have suffered a TBI or any other brain disorder after the TBIcare or PACoS-TBI study will be excluded.\n\nExclusion Criteria (colonoscopy)\n\n* Diagnosis of IBD or other diagnosis besides IBS causing severe GI symptoms, such as microscopic colitis or bile acid diarrhea\n* Poorly controlled celiac disease\n* Colorectal cancer diagnosed within five years\n* Antibiotic or probiotic treatment, on-going or previous month.\n* Unwilling or unable to undergo colonoscopy and\u002For standard bowel preparation.\n* Significantly increased risk of heart or kidney failure or electrolyte imbalances due to bowel preparation (frailty, serious pre-existing heart or kidney insufficiency).\n* Altered bowel anatomy after significant operation. Appendicectomy or cholecystectomy are considered minor operations.",{"count":249,"type":23},"14 Years","The OVERCOME-TBI project aims to collect multimodal data approximately 1-4 and 11-14 years after an earlier well-documented traumatic brain injury (TBI) and examine factors that influence disease progression in order to gain new scientific insights into the long-term pathophysiology of TBI and identify new therapeutic targets.\n\nTBIs are among the most serious health problems worldwide and represents a significant burden for the injured, their families and society. It is estimated that more than 50 million people in the world suffer a TBI every year and half of all people will suffer a TBI in their lifetime. TBI diagnostics has lagged significantly behind that of many other diseases. The current methods for assessing severity and predicting outcomes are based only on initial stage variables, and there are no objective tools for monitoring disease progression. The current acute severity indices have shown only a modest association with outcome, particularly in patients with mTBI. However, even in patients with moderate-severe TBI, clinical predictors and imaging together explain only 35% of the variance in outcomes.\n\nIn the OVERCOME-TBI project, patients with a history of TBI sustained 1-4 and 11-14 years earlier will undergo extensive neurological, biochemical, microbiological, gastroenterological and imaging examinations. The patients have previously participated in the prospective studies of our research group, so that data on acute injuries, blood-based biomarkers and advanced imaging results are already available. The results are expected to yield objective diagnostic and treatment methods for the diagnosis of progressive brain disease after brain injury and for the identification of microbiome-gut-brain axis dysfunction associated with disease progression.",[627],"Traumatic Brain Injury",[629,630,631,632,633,634,635,519,636,637,638,639,640],"traumatic","brain","injury","traumatic brain injury","TBI","neuroinflammation","gut","microbiota-gut-brain axis","DTI","diffusion tensor","biomarker","blood based biomarker","2025-04-11",{"date":643,"type":40},"2025-04-15",{"date":579,"type":23},{"date":237,"type":23},{"name":46,"class":47},{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":18,"minAge":655,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":24,"phases":658,"briefSummary":659,"conditions":660,"keywords":664,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":239},"100588007","sedentary-lifestyle-mortality-and-major-adverse-clinical-outcomes-in-chronic-kidney-disease-100588007","NCT06935786","SEDentary Lifestyle, Mortality and Major Adverse Clinical Outcomes in Chronic KIDney Disease","SEDentary Lifestyle, Mortality and Major Adverse Clinical Outcomes in Chronic KIDney Disease. A Prospective Multicenter Follow-up Protocol With a Nested Randomized Controlled Trial of Physical Education Benefits - The SEDKID Study","SEDKID","Inclusion Criteria:\n\n* Age \\>40 years\n* Estimated glomerular filtration rate \\\u003C 20ml\u002Fmin\u002F1.73m2 (CKD stage 4-5)\n* Informed consent from the patient is received\n\nExclusion Criteria:\n\n* Maintenance dialysis dependency before inclusion\n* Pregnant women\n* Patient's lack of commitment to follow-up\n* Chronic or acute clinical condition with a prognosis less than 6 months\n* Amputated lower limbs","40 Years",{"count":657,"type":23},400,[26],"The goal of this study is to learn if a simple home exercise program can benefit patients with advanced chronic kidney disease. There is also an observational part of the study without an exercise program.\n\nThe study will record patients' mortality, cardiovascular events, emergency department visits, hospital stays, need for dialysis and 6 minutes walking distance. Also maximal oxygen uptake, quality of life and bone fractures are recorded and blood tests and X-rays analyzed. The prospective observational part of the study will investigate the link between cardiovascular and kidney health as well as exercise capacity and adverse outcomes.",[661,662,663],"Chronic Kidney Disease","Cardiovascular Diseases","Frailty",[661,662,665,663,666,667,668,600,669,670],"Renal Replacement Therapy","Mortality","Hospitalisations","Exercise Program","Emergency Department Visit","Major Adverse Cardiovascular and Cerebrovascular Events",{"date":672,"type":40},"2025-04-20",{"date":674,"type":40},"2025-02-21",{"date":676,"type":23},"2031-12-31",{"name":46,"class":47},{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":683,"acronym":684,"eligibilityCriteria":685,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":686,"enrollmentInfo":687,"targetDuration":4,"studyType":24,"phases":689,"briefSummary":690,"conditions":691,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":695,"completionDateStruct":697,"leadSponsor":699,"locationsCount":186},"100459047","fmt-in-initial-cdi-100459047","NCT05257538","FMT in Initial CDI","Fecal Microbiota Transplantation in Initial Clostridioides Difficile Enteritis: a Randomized, Placebo-controlled Trial","FinCDI","Inclusion Criteria:\n\n* \\>18 years\n* C. difficile PCR in feces positive and clinical symptoms of enteritis.\n* Full resolution of diarrhea during antibiotic treatment for C. difficile\n* No other ongoing antibacterial treatments.\n* No ongoing probiotics.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnant\n* Ongoing need for antibacterial treatment\n* Life expectancy \\\u003C 1 year\n* Prior C. difficile infection in preceding 3 months\n* Unable to provide written consent, due to dementia for example.\n* Fecal incontinence i.e. inability to retain enema.","120 Years",{"count":688,"type":23},140,[26],"The study explores fecal microbiota transfer via retention enema after the first clostridioides difficile episode.",[692],"Clostridioides Difficile Infection","2025-04-08",{"date":641,"type":40},{"date":696,"type":40},"2021-08-01",{"date":698,"type":23},"2028-02-28",{"name":46,"class":47},""]